The Institutional Biosafety Committee (IBC) reviews all protocols involving recombinant or synthetic DNA and or Biosafety Level 3 biohazardous agents in both human and non human research. Approval from the IBC is required prior to submission to the Institutional Review Board (IRB).
On March 28, 2025, the National Institutes of Health (NIH) issued a memorandum titled “Implementation Update: Promoting Maximal Transparency Under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.” In alignment with this update, NIH now requires that approved minutes from all Institutional Biosafety Committee (IBC) meetings held on or after June 1, 2025, be made publicly accessible on an institutional website immediately following IBC approval.
Consistent with NIH policy, minutes from meetings held prior to June 1, 2025, that are not posted online will continue to be available to the public upon request.
For questions related to this policy or meetings minutes, please email [email protected] or call 201-389-0198.
Below are the IBC meeting minutes pertaining to human research at Valley Health System since June 1, 2025: